Condition: Acute Myeloid Leukemia With FLT3/ITD Mutation · Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg. After taking the corresponding investigational product, participants are required to complete test procedures including QTc interval measurement , blood sampling, and vital sign monitoring. The entire test process lasts for 3 days. On the third day, after participants complete laboratory tests and are assessed by physicians as meeting the discharge criteria, they can be discharged.
This description comes directly from the study's public registry record.
Jie Hou · +86 0533-7698397 · jie.hou@gohealtharo.com
Wei Wang · 086-0311-66703017 · wangwei001@yiling.cn
Always discuss trial participation with your own doctor first.
| PKUCare Luzhong Hospital | Zibo, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07162116